PD-L1 Antibody (YA4539)(PBS only)
(Synonyms: B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1,CD274)PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.
-
Host:
Mouse
-
Isotype:
IgG2b
-
Application:
IHC-P, FC, ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in PBS, pH 7.4.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
FC
FC: Flow Cytometry
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|
| Dilution Ratio | 1:200-1:1000 | 1:200-1:400 | 1:10000 |
Product Details
PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.
-
Host Mouse
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 46 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 33 kDa
Purified recombinant fragment of human CD274 (AA: 24-153) expressed in E. Coli.
affinity purified.
Non-conjugated
IgG2b
Product Properties
-
Appearance
Liquid
-
Formulation
Supplied in PBS, pH 7.4.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy[1][2][3][4][5][6][7].
-
Subcellular Localization
Cell membrane; Single-pass type I membrane protein; Early endosome membrane; Single-pass type I membrane protein; Recycling endosome membrane; Single-pass type I membrane protein; Nucleus; Cell membrane; Single-pass type I membrane protein; Endomembrane system; Single-pass type I membrane protein; Secreted
-
Expression
Tissue_specificity:It is highly expressed in the heart, skeletal muscle, placenta, and lungs. It is weakly expressed in the thymus, spleen, kidneys, and liver. It is expressed on activated T cells and B cells, dendritic cells, keratinocytes, and monocytes; it is widely expressed, with the highest expression in the lungs, liver, pituitary gland, and various peripheral blood cells (including neutrophils and certain subtypes of lymphocytes and myeloid cells) .
Induction:Up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation. Up-regulated in B-cells activated by surface Ig cross-linking -
Isoforms & Post-Translational Modification
Q9NZQ7 has 4 isomers: Q9NZQ7-1: 33275 Da (predicted); Q9NZQ7-2: 20246 Da (predicted); Q9NZQ7-3: 20454 Da (predicted); Q9NZQ7-4: 28050 Da (predicted).
Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation (PubMed:28813410). Ubiquitinated by MARCHF8; leading to degradation (PubMed:34183449). Deubiquitinated by USP22; leading to stabilization (PubMed:31399419) -
Subunit
Interacts with PDCD1 (PubMed:11015443, PubMed:18287011, PubMed:26602187). Interacts (via transmembrane domain) with CMTM4 and CMTM6 (PubMed:28813410, PubMed:28813417). Interacts with (phosphorylated) STAT3; promoting nuclear translocation (PubMed:32929201). Interacts with CD80 (PubMed:36727298)
-
SwissProt ID
-
Synonyms
B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1,CD274
Documentation
Powered by Bioz
